Table 3 Cox regression hazard model including the maximum grade of total adverse events within the first 6 months for overall survival.

From: Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials

 

Univariable

Multivariable

Characteristics

HR

95% CI

P

HR

95% CI

P

Adverse events

 Grade 0

1 (Reference)

  

1 (Reference)

  

 Grade 1

0.81

(0.64–1.03)

0.089

0.77

(0.61–0.98)

0.035

 Grade 2

0.74

(0.59–0.92)

0.0066

0.70

(0.56–0.87)

0.0017

 Grade 3

0.74

(0.57–0.96)

0.021

0.69

(0.53–0.91)

0.0074

 Grade 4

1.49

(0.83–2.69)

0.18

1.12

(0.62–2.04)

0.71

Age, years

 <70

1 (Reference)

  

1 (Reference)

  

 ≥70

1.34

(1.13–1.59)

0.0008

1.43

(1.21–1.71)

<0.0001

Sex

 Male

1 (Reference)

  

1 (Reference)

  

 Female

0.83

(0.70–0.97)

0.024

0.83

(0.70–0.99)

0.034

BMI, kg/m2

 18.5−25

1 (Reference)

  

1 (Reference)

  

 <18.5

0.96

(0.76–1.22)

0.75

0.94

(0.74–1.20)

0.64

 25>

0.82

(0.65–1.04)

0.11

0.82

(0.65–1.04)

0.10

PS (ECOG)

 0

1 (Reference)

  

1 (Reference)

  

 1, 2

0.78

(0.48–1.29)

0.33

0.74

(0.45–1.22)

0.24

Tumour location

 Colon

1 (Reference)

  

1 (Reference)

  

 Rectum

1.21

(1.03–1.42)

0.024

1.38

(1.16–1.63)

0.0002

Histology

 Well to moderate

1 (Reference)

  

1 (Reference)

  

 Other

2.09

(1.63–2.68)

<0.0001

1.79

(1.39–2.30)

<0.0001

pT-stagea

 T1−3

1 (Reference)

  

1 (Reference)

  

 T4

1.94

(1.64–2.28)

<0.0001

2.03

(1.72–2.40)

<0.0001

pN-stagea

 N0

1 (Reference)

  

1 (Reference)

  

 N1

1.97

(1.42–2.74)

<0.0001

2.65

(1.90–3.70)

<0.0001

 N2

3.97

(2.84–5.57)

<0.0001

4.71

(3.35–6.62)

<0.0001

  1. BMI body mass index, CI confidence interval, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, UICC Union for International Cancer Control, Well to moderate well or moderately differentiated.
  2. aThe pathological T-stage and N-stage are based on UICC version 6.